| Literature DB >> 25422769 |
Parisa Amiri1, Farhad Hosseinpanah1, Sara Jalali-Farahani1, Yadollah Mehrabi2, Ali Montazeri3, Fereidoun Azizi4.
Abstract
AIMS/Entities:
Keywords: Metabolic syndrome; Persistency; Quality of life
Year: 2014 PMID: 25422769 PMCID: PMC4234232 DOI: 10.1111/jdi.12222
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Figure 1The sampling frame of the study.
Definition of study groups based on metabolic syndrome status in three phases of the Tehran Lipid and Glucose Study
| Study groups | Phase III (2005–2008) | Phase II (2001–2004) | Phase I (1997–2000) |
|---|---|---|---|
| Metabolic syndrome status | |||
| Persistent ( | + | + | + |
| Intermittent ( | + | − | + |
| + | + | − | |
| − | + | + | |
| Transient ( | + | − | − |
| − | − | + | |
| − | + | − | |
| Without ( | − | − | − |
Intermittent, those with metabolic syndrome for two phases; Persistent, those with metabolic syndrome for all three phases; Transient, those with metabolic syndrome in just one phase; Without, those without metabolic syndrome in all three phases.
General characteristics of the study sample
| Women ( | Men ( | |||||||
|---|---|---|---|---|---|---|---|---|
| Without ( | Transient ( | Intermittent ( | Persistent ( | Without ( | Transient ( | Intermittent ( | Persistent ( | |
| Age, years (mean ± SD) | 47.96 (10.08) | 50.56 (13.38) | 51.10 (16.11) | 51.52 (12.53) | ||||
| Marital status | ||||||||
| Married | ||||||||
| Educational level | ||||||||
| Primary | 18 (34.0) | 10 (29.4) | 22 (38.6) | 20 (30.8) | ||||
| Secondary | 22 (41.5) | 16 (47.1) | 21 (36.8) | 28 (43.1) | ||||
| Higher | 13 (24.5) | 8 (23.5) | 14 (24.6) | 17 (26.2) | ||||
| Physical activity (MET h/week) (Mean ± SD) | 9.96 (15.92) | 10.19 (14.66) | 10.25 (15.04) | 10.37 (18.12) | 10.09 (16.64) | 18.81 (32.91) | 16.93 (25.64) | 18.17 (33.74) |
| Smoking | ||||||||
| Daily/occasionally | 1 (0.6) | 1 (1.2) | 2 (2.9) | 2 (1.7) | 11 (20.8) | 6 (17.6) | 9 (15.5) | 12 (17.9) |
| Ex-smoker/never smoked | 154 (99.4) | 84 (98.8) | 66 (97.1) | 114 (98.3) | 42 (79.2) | 28 (82.4) | 49 (84.50) | 55 (82.1) |
| Medication | ||||||||
| User | 1 (1.9) | 1 (2.9) | 4 (7.0) | 5 (7.6) | ||||
Data are presented as n (%) unless stated otherwise.
P < 0.001.
Individuals who were taking hypertensive or anti lipid drugs. Intermittent, those with metabolic syndrome for two phases; Persistent, those with metabolic syndrome for all three phases; Transient, those with metabolic syndrome in just one phase; Without, those without metabolic syndrome in all three phases. MET, Metabolic Equivalent Task; SD, standard deviation.
Metabolic syndrome components among study groups by sex
| Women ( | Men ( | |||||||
|---|---|---|---|---|---|---|---|---|
| Without | Transient | Intermittent | Persistent | Without | Transient | Intermittent | Persistent | |
| Waist circumference (cm) | 79.4 ± 1.4 | 87.6 ± 1.6 | 92.6 ± 1.7 | 93.3 ± 1.5 | 85.0 ± 1.9 | 91.6 ± 2.2 | 97.2 ± 1.8 | 104 ± 1.9 |
| Triglycerides (mmol/L) | 1.2 ± 0.1 | 1.6 ± 0.2 | 2.0 ± 0.2 | 2.3 ± 0.1 | 1.0 ± 0.2 | 1.3 ± 0.3 | 1.9 ± 0.2 | 2.5 ± 0.2 |
| Fasting blood sugar (mmol/L) | 4.7 ± 0.06 | 5.0 ± 0.07 | 5.0 ± 0.08 | 5.2 ± 0.07 | 4.8 ± 0.1 | 5.1 ± 0.1 | 5.1 ± 0.1 | 5.3 ± 0.1 |
| High-density lipoprotein (mmol/L) | 1.4 ± 0.04 | 1.2 ± 0.04 | 1.1 ± 0.04 | 1.0 ± 0.04 | 1.2 ± 0.04 | 1.0 ± 0.04 | 1.0 ± 0.04 | 0.9 ± 0.04 |
| Systolic blood pressure (mm/hg) | 110 ± 2.1 | 114 ± 2.5 | 117 ± 2.6 | 127 ± 2.3 | 120 ± 3.5 | 122 ± 4.0 | 129 ± 3.3 | 130 ± 3.5 |
| Diastolic blood pressure (mm/hg) | 68.4 ± 1.3 | 71.4 ± 1.6 | 73.6 ± 1.6 | 76.7 ± 1.4 | 72.5 ± 2.2 | 75.6 ± 2.5 | 77.1 ± 2.1 | 80.4 ± 2.2 |
Data are presented as mean ± standard error, adjusted for age, marital status, education level and medication use. Data are significant at P < 0.001 for all metabolic syndrome components among study groups in both sexes. Intermittent, those with metabolic syndrome for two phases; Persistent, those with metabolic syndrome for all three phases; Transient, those with metabolic syndrome in just one phase; Without, those without metabolic syndrome in all three phases.
Short Form Health Survey scores according to metabolic syndrome status in study groups by sex
| Women ( | Men ( | |||||||
|---|---|---|---|---|---|---|---|---|
| Without | Transient | Intermittent | Persistent | Without | Transient | Intermittent | Persistent | |
| Physical functioning | 81.11 ± 3.29 | 79.41 (3.88) | 74.91 (4.00) | 74.62 (3.54) | 76.67 (4.65) | 79.66 (5.35) | 76.75 (4.51) | 69.88 (4.72) |
| Role physical | 72.72 (5.31) | 69.05 (6.26) | 66.63 (6.45) | 68.85 (5.71) | 57.56 (7.81) | 68.76 (8.99) | 61.03 (7.57) | 67.48 (7.93) |
| Bodily pain | 70.48 (3.62) | 74.04 (4.17) | 71.36 (3.51) | 70.79 (3.68) | ||||
| General health | 62.08 (4.03) | 64.84 (4.64) | 60.24 (3.91) | 60.58 (4.09) | ||||
| Vitality | 60.77 (3.14) | 60.01 (3.71) | 61.91 (3.82) | 57.41 (3.38) | 63.49 (4.41) | 63.87 (5.08) | 61.50 (4.28) | 66.16 (4.48) |
| Social functioning | 80.98 (3.57) | 79.52 (4.21) | 77.90 (4.33) | 76.54 (3.83) | 71.24 (4.88) | 70.10 (5.62) | 68.26 (4.73) | 71.35 (4.96) |
| Role emotional | 69.37 (5.92) | 76.24 (6.99) | 78.64 (7.20) | 77.73 (6.37) | 57.00 (8.74) | 74.36 (10.06) | 52.54 (8.48) | 62.65 (8.88) |
| Mental health | 67.12 (3.04) | 67.09 (3.58) | 66.11 (3.69) | 62.69 (3.27) | 70.71 (4.29) | 70.59 (4.94) | 65.80 (4.16) | 70.56 (4.36) |
Data are presented as mean ± standard error, adjusted for age, marital status, education level and medication use.
P < 0.05 compared to without metabolic syndrome group. Intermittent, those with metabolic syndrome for two phases; Persistent, those with metabolic syndrome for all three phases; Transient, those with metabolic syndrome in just one phase; Without, those without metabolic syndrome in all three phases.
Figure 2Means of the physical and mental component summary scores among study groups in men and women. *P < 0.001. Intermittent, those with metabolic syndrome for two phases; MCS, Mental Component Summary; MetS, metabolic syndrome; PCS, Physical Component Summary; Persistent, those with metabolic syndrome for all three phases; Transient, those with metabolic syndrome for just one phase; Without, those without metabolic syndrome in all three phases.
Results of multiple logistic regression analysis for poor health-related quality of life in men and women
| Women ( | Men ( | |||||
|---|---|---|---|---|---|---|
| Transient | Intermittent | Persistent | Transient | Intermittent | Persistent | |
| PCS | ||||||
| Model 1 | 1.36 (0.77–2.38) | 0.68 (0.24–1.70) | 0.92 (0.43–1.95) | 0.93 (0.45–1.94) | ||
| Model 2 | 1.17 (0.62–2.18) | 1.70 (0.64–4.50) | 0.65 (0.25–1.96) | 0.90 (0.33–2.47) | 1.02 (0.30–3.60) | |
| MCS | ||||||
| Model 1 | 0.87 (0.51–1.48) | 0.68 (0.38–1.20) | 0.90 (0.56–1.46) | 1.25 (0.51–3.03) | 1.78 (0.83–3.83) | 1.06 (0.50–2.25) |
| Model 2 | 0.75 (0.42–1.36) | 0.60 (0.27–1.34) | 0.68 (0.27–1.74) | 1.02 (0.40–2.64) | 0.98 (0.4–2.63) | 0.37 (0.11–1.30) |
Data are presented as Odds Ratio (95% CI), those without metabolic syndrome considered as reference group. PCS: Physical Component Summary, MCS: Mental Component Summary. Model 1. Unadjusted. Model 2. Adjusted for age, marital status, education level, medication use and presence of MetS in phase III. Without: Those without metabolic syndrome in all three phases; Transient: Those with metabolic syndrome in just one phase; Intermittent: Those with metabolic syndrome for two phases; Persistent: Those with metabolic syndrome for all three phases.
P < 0.001 compared to without metabolic syndrome group.